Germany’s Innovative Drug Threshold Removed

Originally, it was proposed that once a revenue threshold of €250 million is exceeded within the first twelve months, the price negotiated between the manufacturer and the GKV-Spitzenverband will apply retrospectively as of the first month following the month in which the threshold was exceeded. While, in general, the deletion of the respective provision is positive, the suggested threshold would have most likely affected only a small number of products but could have been lowered at later stages. Hence, the deletion is positive for industry.

Tagged with

Published 10. March 2017 in News Germany